MedPath

An Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults

Phase 4
Terminated
Conditions
Polypharmacy
Incontinence
Insomnia
Anxiety
Interventions
Behavioral: knowledge transfer tool
Registration Number
NCT01148186
Lead Sponsor
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Brief Summary

An educational intervention targeting community-dwelling older adults will lead to a reduction in potentially inappropriate prescriptions (e.g. benzodiazepines, oxybutynin).

Cessation of potentially inappropriate medications (e.g. benzodiazepines, oxybutynin)will lead to improved cognitive outcomes in older adults.

Detailed Description

This study tests the effectiveness of a knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
300
Inclusion Criteria
  • 65 year old human adults
  • who fill a prescription for at least 5 medications
  • community dwelling
  • chronic use (3 months or longer) of at least one potentially inappropriate medication (e.g. benzodiazepine, oxybutynin)
Exclusion Criteria
  • patients with severe mental illness, dementia and epilepsy
  • concomitant consumption of any other antipsychotic medication (including lithium, olanzapine, clozapine, quetiapine, risperidone, haloperidol etc.)
  • concomitant consumption of any antiepileptic (including carbamazepine, valproate, gabapentin, lamotrigine, topiramate, oxcarbazepine etc.)
  • concomitant consumption of a cholinesterase inhibitor or memantine

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Educational interventionknowledge transfer toolAdministration of an educational intervention to inform patients of the risks and safe alternatives to their current potentially inappropriate medication. The textual content of this knowledge transfer tool will be divided into three parts: a) presentation of the evidence-based risks associated with the targeted potentially inappropriate medication (e.g. benzodiazepines); b) presentation of evidence-based equally or more effective therapeutic substitutes for the medical condition (e.g. insomnia and anxiety); and c) presentation of evidence based tapering recommendations where applicable.
Primary Outcome Measures
NameTimeMethod
Complete discontinuation of the targeted potentially inappropriate medication (e.g. benzodiazepines, oxybutynin)6 months post-intervention
Secondary Outcome Measures
NameTimeMethod
Cognitive function6-months post-intervention

Montreal cognitive assessment instrument Rey's auditory verbal learning test (immediate memory, learning, and delayed recall)

Sleep efficiency6-months

Sleep efficiency as documented with a sleep diary

incontinence-related self-efficacy6-months post-intervention

incontinence-related self-efficacy as measured with the geriatric self-efficacy index

frequency of urinary incontinence episodes6-months post-intervention

frequency of urinary incontinence as measured with a 72-hour bladder diary

Trial Locations

Locations (1)

Le Groupe Jean Coutu Inc.

🇨🇦

Longueuil, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath